Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides.
Treatment with statins reduces coronary risk In all people but do not remove the risk associated with a low HDL-C or with other features of the metabolic syndrome such as an elevated level of plasma triglyceride or with a high BMI. Treatment with a fibrate such as gemfibrozil (a PPAR alpha agonist) has been shown to be especially effective in people with low HDL-C and other features of the metabolic syndrome. Potential beneficial effects of the combination of a statin and an agent with PPAR alpha activity in patients with type 2 diabetes is currently being addressed in the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study.
Barter
Philip
P
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia. p.barter@hri.org.au
D050197:Atherosclerosis / Q000209:etiology* / Q000378:metabolism* / Q000517:prevention & control; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000378:metabolism; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism; D012306:Risk; D012307:Risk Factors; D014280:Triglycerides / Q000378:metabolism*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D047493:PPAR alpha; D014280:Triglycerides